Vistin Pharma ASA

OB:VISTN Stock Report

Market Cap: NOK 1.1b

Vistin Pharma Management

Management criteria checks 3/4

Vistin Pharma's CEO is Magnus Tolleshaug, appointed in Feb 2022, has a tenure of 3.33 years. total yearly compensation is NOK3.56M, comprised of 72.7% salary and 27.3% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth NOK1.82M. The average tenure of the management team and the board of directors is 3.3 years and 5 years respectively.

Key information

Magnus Tolleshaug

Chief executive officer

NOK 3.6m

Total compensation

CEO salary percentage72.69%
CEO tenure3.3yrs
CEO ownership0.2%
Management average tenure3.3yrs
Board average tenure5yrs

Recent management updates

We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation

May 16
We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation

Recent updates

Vistin Pharma's (OB:VISTN) Shareholders Will Receive A Bigger Dividend Than Last Year

May 23
Vistin Pharma's (OB:VISTN) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation

May 16
We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation

Vistin Pharma (OB:VISTN) Is Paying Out A Larger Dividend Than Last Year

Apr 30
Vistin Pharma (OB:VISTN) Is Paying Out A Larger Dividend Than Last Year

Vistin Pharma's (OB:VISTN) Upcoming Dividend Will Be Larger Than Last Year's

Feb 16
Vistin Pharma's (OB:VISTN) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Sep 18
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Sep 09
A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Aug 25
Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Mar 15
Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20
We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08
The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16
Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26
Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

CEO Compensation Analysis

How has Magnus Tolleshaug's remuneration changed compared to Vistin Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

NOK 77m

Dec 31 2024NOK 4mNOK 3m

NOK 63m

Sep 30 2024n/an/a

NOK 61m

Jun 30 2024n/an/a

NOK 68m

Mar 31 2024n/an/a

NOK 56m

Dec 31 2023NOK 2mNOK 2m

NOK 46m

Sep 30 2023n/an/a

NOK 45m

Jun 30 2023n/an/a

NOK 14m

Mar 31 2023n/an/a

NOK 7m

Dec 31 2022NOK 3mNOK 2m

-NOK 5m

Sep 30 2022n/an/a

-NOK 15m

Jun 30 2022n/an/a

-NOK 7m

Mar 31 2022n/an/a

NOK 929k

Dec 31 2021NOK 2mNOK 1m

NOK 25m

Sep 30 2021n/an/a

NOK 26m

Jun 30 2021n/an/a

NOK 30m

Mar 31 2021n/an/a

NOK 43m

Dec 31 2020NOK 2mNOK 1m

-NOK 97m

Compensation vs Market: Magnus's total compensation ($USD359.87K) is about average for companies of similar size in the Norwegian market ($USD350.02K).

Compensation vs Earnings: Magnus's compensation has increased by more than 20% in the past year.

CEO

Magnus Tolleshaug

3.3yrs
Tenure
NOK 3,563,000
Compensation

Mr. Magnus Tolleshaug served as a Commercial Director at Vistin Pharma ASA and served as its Interim Chief Executive Officer since February 16, 2022 until January 1, 2024 and serves as its Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Magnus Tolleshaug
Chief Executive Officer3.3yrsNOK 3.56m0.17%
NOK 1.8m
Alexander Karlsen
Chief Financial Officer5.3yrsNOK 2.99m0.11%
NOK 1.2m
Vegard Heggem
Chief Operating Officer1.4yrsNOK 2.87m0.17%
NOK 1.9m
Eivind Egeli
Director of Technical Service & Salesno datano datano data
3.3yrs
Average Tenure

Experienced Management: VISTN's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oyvin Broymer
Independent Chairman of the Board5yrsNOK 485.00kno data
Oystein Spetalen
Independent Director10.4yrsNOK 240.00k0.73%
NOK 7.9m
Bettina Banoun
Independent Director7.1yrsNOK 265.00kno data
Kari Krogstad
Independent Director5yrsNOK 240.00kno data
Kjell-Erik Nordby
Observer1.4yrsNOK 240.00k0.32%
NOK 3.4m
Åse Musum
Employee Representative Director10.4yrsNOK 240.00k0.0050%
NOK 53.4k
Nils Ødegaard
Directorless than a yearno datano data
Espen Marcussen
Independent Director5.1yrsNOK 240.00kno data
Espen Gregoriussen
Employee Representative Director7.7yrsNOK 240.00kno data
Eivind Devold
Directorless than a yearno datano data
5.0yrs
Average Tenure
63yo
Average Age

Experienced Board: VISTN's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/16 08:16
End of Day Share Price 2025/06/13 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mikkel Nyholt-SmedsengCarnegie Investment Bank AB